Key result
Chronic NOS inhibition in rats enhanced contractile sensitivity to alpha2-adrenergic receptor agonists, with endogenous NO regulating RhoA activation and chronic inhibition causing RhoA desensitization.
Endogenous NO may regulate RhoA activation, while chronic NOS inhibition appears to cause RhoA desensitization in rat aorta.
Animal findings warrant cautious interpretation; leaves open relevance of NO-RhoA signaling to human vascular control.
We demonstrated that arteries from rats made hypertensive with chronic nitric oxide (NO) synthase (NOS) inhibition (N(omega)-nitro-L-arginine in drinking water, LHR) have enhanced contractile sensitivity to alpha(2)-adrenergic receptors (alpha(2)-AR) agonist UK-14304 compared with arteries from normotensive rats (NR). NO may regulate vascular tone in part through suppression of RhoA and Rho kinase (ROK). We hypothesized that enhanced RhoA and ROK activity augments alpha(2)-AR contraction in LHR aortic rings. Y-27632 eliminated UK-14304 contraction in LHR and NR aortic rings. The order of increasing sensitivity to Y-27632 was the following: endothelium-intact NR, LHR, and endothelium-denuded NR. UK-14304 stimulated RhoA translocation to the membrane fraction in LHR and denuded NR but not in intact NR aorta. Basally, more RhoA was present in the membrane fraction in denuded NR than in intact NR or LHR aorta. Relaxation to S-nitroso-N-acetyl-penicillamine and Y-27632 in denuded ionomycin-permeabilized rings was greater in NR than in LHR. Together these studies indicate alpha(2)-AR contraction depends on ROK activity more in NR than LHR aorta. Additionally, endogenous NO may regulate RhoA activation, whereas chronic NOS inhibition appears to cause RhoA desensitization.
No takes yet. Share an insight, caveat, or question.
Carter et al. (2002) studied Hypertension. Chronic nitric oxide synthase (NOS) inhibition vs. Normotensive rats was evaluated on Contractile sensitivity to alpha2-adrenergic receptors agonist UK-14304 and RhoA/ROK activity. Chronic NOS inhibition in rats enhanced contractile sensitivity to alpha2-adrenergic receptor agonists, with endogenous NO regulating RhoA activation and chronic inhibition causing RhoA desensitization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: